Dr. Zweit is a professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit’s research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the “world’s first” Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas. Dr. Zweit is a professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit’s research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the “world’s first” Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.

Radiation Oncology